Dendreon may be on its last legs, but former CEO Mitchell Gold is happily entrenched in other projects: He’s launching a next-generation immunotherapy startup called Alpine Immune Sciences, seeding about $1.3 million into the company through his investment firm, Alpine BioVentures. It’ll be a recombinant protein-based therapeutic, Gold told MedCity News – and unrelated to the platform used by Dendreon. Beyond […]
Last week, the Cleveland Clinic put out the 2013 version of its Top 10 Medical Innovations, an annual list of medical technologies that it expects to have the biggest impact on healthcare in 2013. At the top of the list was bariatric surgery for diabetes, followed by neuromodulation therapy for headaches. Although the Clinic […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Life science current events this week including Dendreon cuts deal with GSK over poor prostate cancer drug sales, BioDelivery Sciences International on track for a New Drug Application filing in 2012 and Neoprobe outlines approval plan for colorectal cancer drug.
The impact of slow sales of Dendreon‘s (NASDAQ:DNDN) prostate cancer treatment Provenge is reaching pharma giant GlaxoSmithKline (NYSE:GSK). Seattle biotech company Dendreon is terminating a supply contract it signed a year ago that called for GSK to supply antigen intended for the manufacture of Provenge. Dendreon said in securities filings that it gave 60 days […]
North Carolina biotechnology company BioCryst (NASDAQ:BCRX) remains on schedule developing its various drug programs and the company is well capitalized. CEO Jon Stonehouse said the company’s $72 million in cash is enough to last the company two years. Yet on a morning that saw the company disclose nothing remotely controversial during its quarterly conference call, […]
The recommendation that Medicare pay for Provenge should be trigger greater scrutiny on the treatment. The federal government - at least - should use the coverage with evidence development program to review the treatment and find out if it's worth the $2 billion reimbursement price tag.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Health insurers last year gave the U.S. Chamber of Commerce $86.2 million that was used to oppose the healthcare overhaul law, according to tax records and people familiar with the donation, Bloomberg Businessweek reports.
Highlights of the important and the interesting from the world of healthcare: 35,000 pharma layoffs so far this year: While that number sounds scary, remember that it could always be worse. The amount of pharma layoffs in the first half of this year plunged 32 percent compared to the first six months of last year. […]
Highlights of the important and the interesting from the world of healthcare: The case for private-practice primary care: There’s been lots of handwringing in recent years about the slow and continuing disappearance of private-practice physicians. The reasons are numerous–including the obvious (finances) and the slightly less-obvious (hassles with insurance companies). As private-practice primary care docs […]